Skip to main content

Advertisement

Table 1 Patients demographics and baseline characteristics (Full Analysis Set)

From: Efficacy and safety of single injection of cross-linked sodium hyaluronate vs. three injections of high molecular weight sodium hyaluronate for osteoarthritis of the knee: a double-blind, randomized, multi-center, non-inferiority study

  HMWHA XLHA P-value
(N = 146) (N = 137)
Sex
 Male 26 (19%) 32 (22%) 0.54A
 Female 111 (81%) 114 (78%)  
Age, years 62.38 (8.43) 61.97 (8.64) 0.68B
BMI, kg/m2 24.82 (2.65) 25.14 (2.91) 0.52C
Affected knee, patients
 Left 23 (15.75) 22 (16.06) 0.67A
 Right 26 (17.81) 30 (21.90)  
 Bilateral 97 (66.44) 85 (62.04)  
Duration of knee OA, years
 Left 3.08 (0.08,26) 3.83 (0.08, 22.08) 0.98C
 Right 3 (0.08, 26) 4 (0.08, 24.08) 0.19C
K-L grade, patients
 Grade I 28 (19.18) 19 (13.87) 0.36A
 Grade II 65 (44.52) 59 (43.07)  
 Grade III 53 (36.30) 59 (43.07)  
100 mm VAS on WBP 61.01 (13.22) 61.79 (13.76) 0.68C
WOMAC index
 Pain subscore 10.56 (3.31) 10.26 (3.05) 0.33C
 Function subscore 34.53 (11.64) 33.75 (10.53) 0.56B
 Stiffness subscore 3.97 (1.72) 3.87 (1.61) 0.72C
 Total score 49.05 (16.01) 47.88 (14.18) 0.52C
  1. BMI Body mass index, OA osteoarthritis, K-L Kellgren-Lawrence, VAS visual analogue scale, WBP weight bearing pain, WOMAC Western Ontario and McMaster Universities Osteoarthritis. Continuous variables are presented with mean (SD) except duration of knee OA, which is presented with median (min, max)
  2. A, P-value obtained from Chi-square test; B, P-value obtained from two-sample t-test; C, P-value obtained from Wilcoxon’s rank sum test